Cyclobenzaprine added to pain relief after minimally invasive hysterectomy
Tests adding cyclobenzaprine to usual pain medicine in adults after hysterectomy.
Plain-language title generated from the registry record
Registry title: Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy
Key facts
- Where
- Newark, United StatesSee the site
- Phase
- Phase 4
Where in United States
- ChristianaCare Health SystemNewark, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Christiana Care Health Services
- Trial code
- NCT07664956
- Record updated
- 24 June 2026
- Original description
Typical postoperative pain control after minimally invasive hysterectomy includes ibuprofen, acetaminophen, and a short course of narcotics. The purpose of this study is to see if adding cyclobenzaprine to this regime improves pain control and lessens narcotic use.Read full original descriptionShow less
Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy: A Randomized Controlled Trial
Typical postoperative pain control after minimally invasive hysterectomy includes ibuprofen, acetaminophen, and a short course of narcotics. The purpose of this study is to see if adding cyclobenzaprine to this regime improves pain control and lessens narcotic use.
Inclusion: Age >18yo; Female; English speaking; Undergoing (robotic assisted or classic) total laparoscopic hysterectomy ± unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy; If other procedures such as lysis of adhesions, excision of endometriosis, or ureterolysis are indicated based on intraoperative evaluation, those patients may still be included; Surgery took place at ChristianaCare Hospitals; No allergies or contraindications to standard of care post operative pain medications (acetaminophen, NSAIDs, narcotics) or cyclobenzaprine.
Exclusion: Laparoscopic resection of endometriosis; Procedures with planned or unplanned bladder or bowel surgery; Currently using opioids consistently; Patient's receiving gabapentin at baseline or postoperatively, due to potential sedating effects, or other sedating drugs such as scheduled benzodiazepines and barbiturates; Allergies or contraindications to standard post operative pain control medications (acetaminophen, NSAIDs, narcotics), such as kidney or liver damage/failure, bariatric surgery, history of gastric ulcer, etc; Currently undergoing medication assisted treatment for opioid use disorder; Allergies or contraindications to cyclobenzaprine:; Absolute: use of MAO inhibitors within 14 days, recent heart attack, congestive heart failure, heart block or other conduction abnormalities, cardiac arrhythmias, hyperthyroidism, history of serotonin syndrome; Allergies or contraindications to inactive ingredients in Flexeril, such as lactose; Age <18yo; Male; Pregnant, breastfeeding; Non-English speaking; Primary procedures other than laparoscopic hysterectomy; Laparoscopic myomectomy; Laparoscopic unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy ± unilateral or bilateral cystectomy without hysterectomy; Hysteroscopic procedures; Bartholin gland marsupialization; Operations that are scheduled as or converted to the open approach; Chronic pain issues, whether self-diagnosed or by a physician, currently undergoing management.